Results 121 to 130 of about 231,974 (295)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis [PDF]

Case Reports in Gastroenterology, 2011
Autoimmune pancreatitis (AIP), in contrast to other benign chronic pancreatic diseases, can be cured with immunosuppressant drugs, thus the differentiation of AIP from pancreatic cancer is of particular interest in clinical practice. There is the possibility that some patients with AIP may develop pancreatic cancer, and this possibility contributes to ...
Pezzilli R, Vecchiarelli S, Di Marco MC, Serra C, SANTINI, DAVIDE, Calculli L, FABBRI, DARIO, Rojas Mena B, Imbrogno A, Source Pancreas Unit Department of Digestive Diseases and Internal Medicine University of Bologna Bologna Italy.   +9 more
openaire   +4 more sources

The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas

Tumor Biology, 2017
Pancreatic ductal adenocarcinoma is a highly malignant tumor with poor prognosis, and the biomarkers for the early diagnosis, targeting therapy, and prognosis are still not clinically available.
Xin Luo, Zhulin Yang, Xiao Liu, Ziru Liu, Xiongying Miao, Daiqiang Li, Qiong Zou, Yuan Yuan   +7 more
doaj   +1 more source

Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development. [PDF]

, 2019
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease with no efficacious treatment options. PDAC incidence is projected to increase, which may be caused at least partially by the obesity epidemic.
Eibl, Guido, Rozengurt, Enrique
core  

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]

, 2017
Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul, D'Costa, Zenobia, Diana, Angela, Dushek, Omer, Fokas, Emmanouil, Jones, Keaton, Kruger, Philipp, Liu, Stanley, McKenna, W. Gillies, Muschel, Ruth J., Sansom, Owen J., Yin Lim, Su   +11 more
core   +1 more source

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. [PDF]

, 2018
BACKGROUND:Although canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant K-Ras, the detailed molecular mechanisms by which the Wnt effector β-catenin regulates such ...
Chen, Yibu, Genyk, Yuri S, Kahn, Michael, Lai, Keane KY, Lenz, Heinz-Josef, Lin, David P, Manegold, Philipp, Nguyen, Cu, Pandol, Stephen J, Teo, Jia-Ling, Wu, Kaijin, Wu, Yongfeng, Zhao, Yi   +12 more
core   +2 more sources

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer [PDF]

, 2017
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative ...
Andersen, Jesper B., Arricibita, Andrea, Bailey, Peter, Biankin, Andrew, Bozec, Aline, Chang, David K., Chuang, Chen-Hua, Guembe, Laura, Guruceaga, Elisabet, Gwinn, Dana, Khatri, Purvesh, Lecanda, Fernando, Martinez-Canarias, Susana, Mazur, Pawel K., Perurena, Naiara, Ponz-Sarvise, Mariano, Sage, Julien, Sayles, Leanne C., Sweet-Cordero, E. Alejandro, Valencia, Karmele, Vallejo, Adrian, Vicent, Silve, Zandueta, Carolina   +22 more
core   +3 more sources

Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma.

Cancer Discovery, 2020
MYC is implicated in the development and progression of Pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumour development has been difficult to define. We used modestly elevated expression of human MYC, driven from
Nathiya Muthalagu, T. Monteverde, X. Raffo-Iraolagoitia, R. Wiesheu, D. Whyte, A. Hedley, S. Laing, Björn Kruspig, R. Upstill-Goddard, R. Shaw, Sarah Neidler, Curtis Rink, S. Karim, K. Gyurászová, C. Nixon, W. Clark, A. Biankin, L. Carlin, S. Coffelt, O. Sansom, J. Morton, D. Murphy   +21 more
semanticscholar   +1 more source

Biomarkers in pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego, C. López, R. Pazo-Cid, F. López-Ríos, A. Carrato   +4 more
openaire   +3 more sources

Emerging concepts in the management of pancreatic ductal adenocarcinoma

Laparoscopic, Endoscopic and Robotic Surgery, 2019
Pancreatic ductal adenocarcinoma is characterised by poor oncological outcomes with curative treatment only possible for a minority. Symptoms are dependent on the stage of the disease and location within the pancreas with constitutional decline often ...
Sanket Srinivasa, Rowan Parks
doaj   +1 more source

Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells [PDF]

, 2017
Previous results link the mitochondrial potassium channel Kv1.3 (mitoKv1.3) to the regulation of apoptosis. By synthesizing new, mitochondria-targeted derivatives (PAPTP and PCARBTP) of PAP-1, a specific membrane-permeant Kv1.3 inhibitor, we have ...
Amigorena, Arcangeli, Beeton, Cahalan, Checchetto, Chittajallu, Cholo, Cidad, Comes, Connor, Deutsch, Diebold, Diwakarla, Doyle, Erdogan, Esteras, Fraser, Ghiani, Heginbotham, Hinz, Hu, Jang, Koren, Leanza, Leanza, Leanza, Lin, Long, Lu, Malinska, Manago, Nilius, Pardo, Peruzzo, Ralph, Ralph, Rauer, Shieh, Siegel, Szabo, Szabo, Tegla, Tonks, Urrego, Van Rensburg, Xu, Zaccagnino, Zhou, Zucca   +48 more
core   +2 more sources